Treating to target in psoriatic arthritis: how to implement in clinical practice.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26672066.
- Also identified by DOI 10.1136/annrheumdis-2015-208617.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treating to target is becoming the standard of care in many medical specialities, including rheumatology. The Tight Control of Psoriatic Arthritis (TICOPA) trial has recently provided evidence of the benefit of treating to target in psoriatic arthritis (PsA), and the revised European League Against Rheumatism (EULAR) recommendations on the management of PsA suggest this approach. However, the question of the optimal measure to use and the practicalities of incorporating this into routine clinical practice remain problematic.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Psoriatic
- Outcome Assessment, Health Care